Belinostat(PXD-101)(CAS: 414864-00-9)

Belinostat (CAS: 414864-00-9) falls under the regulatory guidelines of the Chemicals in the European Union (REACH) and the U.S. Food and Drug Administration (FDA). It is classified under the Globally Harmonized System of Classification and Labelling of Chemicals (GHS) as a substance that may cause skin irritation and sensitization. Specific testing and documentation requirements for handling, storage, and transportation are mandated under REACH and OSHA (Occupational Safety and Health Administration) guidelines.

There are several alternatives to Belinostat (CAS: 414864-00-9) in synthesis, such as other histone deacetylase inhibitors (HDACi) likeentinostat and mocetinostat. These compounds can serve as viable alternatives depending on the specific requirements of the synthesis process. Additionally, researchers often explore use of common reagents like sodium acetate and ethanol in the synthesis of related compounds.

The market and research trend for Belinostat (CAS: 414864-00-9) is focused on its use as an antineoplastic agent, particularly in the treatment of hematologic malignancies and solid tumors. Recent trends indicate a growing interest in its combination therapies and the exploration of its mechanism of action. Research is also expanding into the development of more potent and selective HDAC inhibitors to improve efficacy and reduce side effects.

Waste containing Belinostat (CAS: 414864-00-9) should be collected in properly labeled, sealed containers and stored in a safe, secure area. Disposal should be handled by a certified hazardous waste management company. Incineration is a common method, but other professional waste disposal services may be required depending on local regulations. Environmental precautions include ensuring that no waste is released into the environment and that all handlers follow safety protocols to prevent exposure.